Toric IOL performance and constants optimization after cataract surgery
Official title: Prospective Assessment of Constant Optimization and Visual Outcomes Following Monofocal Toric IOL Implantation
Run by Carl Zeiss Meditec AG · NCT07471295 · Data updated 2026-11-12
This test checks the safety and how well a monofocal toric intraocular lens performs, to fine-tune its power settings for people undergoing cataract surgery.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 130 (estimated) |
| Sponsor | Carl Zeiss Meditec AG Industry-sponsored |
| Locations | 6 sites (Prague, Prague and 5 other locations) |
| Status | Recruiting |
| Started | July 13, 2026 |
| Main results expected | February 28, 2028 |
| Study ends | February 28, 2028 |
| Registry record updated | July 22, 2026 |
| Trial ID | NCT07471295 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older with clinically significant cataract, regular corneal astigmatism (≥0.75 D in the operated eye), and planned unilateral or bilateral phacoemulsification or femtosecond-laser-assisted cataract surgery.
✕Probably not a fit
Patients outside the specified IOL power or cylinder ranges, or those lacking adequate follow-up, may not experience diagnostic or treatment benefits.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 4 interventional study evaluates a monofocal toric intraocular lens by focusing on safety and refractive outcomes to optimize IOL constants. Eligible adults with age-related cataract and regular corneal astigmatism will undergo cataract surgery with the investigational lens, and refractive results will guide adjustments in lens constants. The trial involves follow-up exams to assess visual acuity, refractive accuracy, and axis alignment postoperatively. Multisite participation includes centers in Prague and Heidelberg, sponsored by Carl Zeiss Meditec AG with targomedGmbH as a collaborator.
Why it matters
Potential benefit: If successful, participants may experience better alignment and refractive outcomes with the toric IOL, potentially improving uncorrected vision after surgery.
How similar studies have gone: Prior studies of toric IOLs have shown favorable outcomes with optimized constants; this study focuses on refining those constants in a real-world setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 years or older; * Patients willing, able, and with sufficient cognitive awareness to comply with examination procedures and schedule for follow-up visits; * Patients with clinically significant age-related cataract (cataract grades of 1, 2, 3 on the LOCSIII scale, but otherwise healthy, requiring surgical treatment, and scheduled for unilateral or bilateral phacoemulsification or Femtosecond-Laser-Assisted cataract surgery; * Patients with existing regular corneal astigmatism of minimum 0.75 D in at least the first eye to be operated. * Signed informed consent form; * Corrected distance visual acuity projected to be better than 0.2 logMAR after the cataract surgery, as determined by Investigator's medical judgment; * Calculated IOL power within the range of the investigational IOL; SE +18.0 D to +28.0 D (0.5 D Steps), and between a Cylinder range of +1.0 D to +2.5 D (0.5 D Steps); * Dilated pupil size large enough to visualize TIOL axis markings postoperatively; at least 5.5mm; * Clear intraocular media other than cataract. Exclusion Criteria: * Previous intraocular or corneal surgery in either eye that might confound the outcome of the study or increase the risk to the subject; * Keratometric astigmatism (assessed by IOL Master) of minimum 0.75 D in the first eye * Traumatic cataract; * Pregnancy or lactation; * Concurrent participation in another drug or device investigation within the last 30 days; * Irregular astigmatism; * Instability of keratometry or biometry measurements; * Subjects wearing contact lenses as standard vision aid; * Abnormal pupil; * Any anterior segment pathology that could significantly affect outcomes (e.g. chronic or recurrent uveitis, iritis, aniridia, rubeosis iridis, etc.); * History of concurrent intraocular inflammation; * Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal degeneration, or clinically significant corneal membrane dystrophies); * History of any clinically significant retinal or ocular pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerve atrophy, amblyopia, strabismus, microphthalmus, epiretinal membrane, Choroidal hemorrhage etc.) in the study eyes that could alter or limit final postoperative visual prognosis; * Pseudoexfoliation syndrome (according to investigator judgement); * Uncontrolled glaucoma or IOP higher than 24mmHg under ocular hypertension treatment; * All kind of infections (acute ocular disease, external / internal infection, systemic infection); * Monophthalmic patient; * Patients, who are unable to fixate for a longer time, e.g. strabismus, nystagmus, Parkinson disease * Patient expected to require retinal laser treatment before the end of the last follow-up examination; * Patient expected to require refractive laser treatment / refractive laser touch-up before the end of the last follow-up examination; * Patients who may be reasonably expected to require a secondary surgical intervention at any time during the investigation (other than Nd:YAG capsulotomy) * In case of both eyes included in this trial: Patients who need to undergo surgery on both eyes on the same day
Where it's running
-
Oční klinikaO
Prague, Prague, Czechia Recruiting -
Oční Centrum Praha
Prague, Czechia Recruiting -
Ofatlivist Alicante
Alicante, Spain Recruiting -
Universitätsklinikum Heidelberg
Heidelberg, Germany Not yet recruiting -
PVK Precise Vision GmbH
Rheine, Germany Not yet recruiting -
Ayrshire Eye Clinic
Ayr, Ayrshire, United Kingdom Not yet recruiting
Study contacts
- Principal investigator: Gerd Auffarth, Dr. Med — University Hospital Heidelberg
- Study coordinator: Grant Sharpe
- Email: grant.sharpe@zeiss.com
- Phone: +447918937014
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rotational Stability of the Acunex Vario Toric
This study tests whether the Acunex Vario toric extended-depth-of-focus intraocular lens stays stable in rotation and effectively reduces astigmatism for people undergoing cataract surgery.
-
Anterior segment anatomy assessment with swept-source OCT in eye surgery patients
This study tests whether swept-source OCT can detail front-eye anatomy in patients undergoing anterior segment eye surgery.
-
MiLOOP-assisted cataract surgery for dense cataracts
In people with dense cataracts, this study tests whether using the miLOOP device during cataract surgery can protect corneal cells and reduce ultrasound energy, compared with standard surgery.
-
Visual adaptation and quality of life after different IOL implantation options
This study follows adults who have cataracts and receive bilateral multifocal or mixed IOLs to see how their vision and daily life improve over 6 months.
-
Corneal Biomechanics and Surgical Astigmatism after Cataract Surgery in Pseudoexfoliation
This study tests how the cornea's biomechanical properties before cataract surgery relate to the amount of blinking surgically induced astigmatism, comparing people with pseudoexfoliation to those without.
-
Neuroplastic pain education and guided breathing during awake cataract surgery
This trial tests whether the STEIN Protocol, a non-drug approach with pain education, guided imagery, and paced breathing, helps adults having cataract surgery require less pain medicine and feel less anxious.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.